Creative Medical Technology Holdings, Inc.CELZ

CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) told the SEC on 24 July 2026 that it proposes to register up to 18.8 million additional shares for issuance under its existing shelf facility, a move that would more than quintuple its diluted share count if all warrants and options are exercised. The company’s latest 10-Q for the quarter ended 31 March 2026 shows $0 revenue, a $1.4 million net loss, and $6.4 million in total assets, leaving little cushion for the $1.5 million severance package disclosed in the 14 July 2026 proxy statement.

The company markets a pipeline of cell-based therapies: ImmCelz™ for brittle Type 1 diabetes (granted Orphan Drug Designation by the FDA in March 2024), and AlloStemSpine® for chronic lower back pain (FDA-cleared Phase I/II trial opened in September 2023). It also operates the CREATE-1 clinical trial for newly diagnosed Type 1 diabetes using AlloStem™ (CELZ-201). None of these programmes have generated product revenue to date, and the company’s 10-Q shows no inventory build ($125,000 flat versus prior quarter) and a net cash used in operating activities of $1.3 million for the quarter.

The SEC filings confirm the company’s operating loss widened to $1.5 million in the quarter, with $541,658 spent on R&D and a diluted loss per share of $0.38 on 3.7 million diluted shares. The company’s balance sheet lists $6.1 million in stockholders’ equity, comfortably outstripping its $307,649 in liabilities, but the gap between preclinical hope and commercial traction remains the salient feature of the story. The filings do not quantify near-term revenue milestones, clinical readouts, or regulatory catalysts beyond the Orphan Drug Designation already secured (source: CELZ 10-Q, 2026-03-31, https://www.sec.gov/Archives/edgar/data/1187953/000147793226004097/celz_rw.htm; CELZ S-3, 2026-07-24, https://www.sec.gov/Archives/edgar/data/1187953/000147793226004498/celz_s3.htm; CELZ DEF 14A, 2026-07-14, https://www.sec.gov/Archives/edgar/data/1187953/000147793226004302/celz_def14a.htm).

The company’s clinical programme pages and product imagery are hosted on its own website and link to external trial registries, but the filings do not provide endpoints, timelines, or interim efficacy data. The source requires readers to therefore balance the visual promise of cell-based therapies against the absence of measurable sales, cash metrics, or audited financials beyond the latest 10-Q. For now, the equity trades on narrative rather than numbers (source: Clinical Trials & Registries, https://www.creativemedicaltechnology.com/clinical-trials-registries; Clinical Trials | Type 1 Diabetes, https://www.creativemedicaltechnology.com/clinical-trials-type-1-diabetes).